CADRENAL THERAPEUTICS INC (CVKD) Stock Price & Overview
NASDAQ:CVKD • US1276362076
Current stock price
The current stock price of CVKD is 5.86 USD. Today CVKD is up by 8.92%. In the past month the price increased by 2.27%. In the past year, price decreased by -65.12%.
CVKD Key Statistics
- Market Cap
- 14.709M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.70
- Dividend Yield
- N/A
CVKD Stock Performance
CVKD Stock Chart
CVKD Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CVKD. When comparing the yearly performance of all stocks, CVKD is a bad performer in the overall market: 93.58% of all stocks are doing better.
CVKD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CVKD. The financial health of CVKD is average, but there are quite some concerns on its profitability.
CVKD Earnings
CVKD Forecast & Estimates
7 analysts have analysed CVKD and the average price target is 28.22 USD. This implies a price increase of 381.57% is expected in the next year compared to the current price of 5.86.
CVKD Groups
Sector & Classification
CVKD Financial Highlights
Over the last trailing twelve months CVKD reported a non-GAAP Earnings per Share(EPS) of -6.7. The EPS increased by 22.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -305.95% | ||
| ROE | -483.35% | ||
| Debt/Equity | 0 |
CVKD Ownership
CVKD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.35 | 853.191B | ||
| JNJ | JOHNSON & JOHNSON | 17.82 | 544.731B | ||
| MRK | MERCK & CO. INC. | 22.17 | 278.01B | ||
| PFE | PFIZER INC | 8.97 | 155.349B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.29 | 121.259B | ||
| ZTS | ZOETIS INC | 16.62 | 49.697B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 28.547B | ||
| VTRS | VIATRIS INC | 5.82 | 17.152B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.35 | 11.291B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.359B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.199B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.101B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.82 | 4.797B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CVKD
Company Profile
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 4 full-time employees. The company went IPO on 2023-01-20. The company has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
Company Info
IPO: 2023-01-20
CADRENAL THERAPEUTICS INC
822 A1a North, Suite 306
Ponte Vedra FLORIDA US
Employees: 4
Phone: 13026587581
CADRENAL THERAPEUTICS INC / CVKD FAQ
What does CADRENAL THERAPEUTICS INC do?
Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. The company is headquartered in Ponte Vedra, Florida and currently employs 4 full-time employees. The company went IPO on 2023-01-20. The company has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
What is the stock price of CADRENAL THERAPEUTICS INC today?
The current stock price of CVKD is 5.86 USD. The price increased by 8.92% in the last trading session.
Does CVKD stock pay dividends?
CVKD does not pay a dividend.
What is the ChartMill technical and fundamental rating of CVKD stock?
CVKD has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for CVKD stock?
7 analysts have analysed CVKD and the average price target is 28.22 USD. This implies a price increase of 381.57% is expected in the next year compared to the current price of 5.86.
How many employees does CADRENAL THERAPEUTICS INC have?
CADRENAL THERAPEUTICS INC (CVKD) currently has 4 employees.
What is the market capitalization of CVKD stock?
CADRENAL THERAPEUTICS INC (CVKD) has a market capitalization of 14.71M USD. This makes CVKD a Nano Cap stock.